Quick answer: under Canada peptide regulations, injectable peptides are treated as prescription drugs under the Food and Drugs Act, so only Health Canada-authorized products with an 8-digit Drug Identification Number (DIN), dispensed on a prescription, are legal to sell.[1][3] Peptides sold online as “research use only” are not exempt, and Health Canada has seized dozens of them, including BPC-157, TB-500 and retatrutide.[3][4]
This guide explains the laws, which agency enforces them, and what changed in 2025 and 2026. For the wider picture, see our FDA and regulation hub, our country-by-country peptide legality table and how rules differ in the EU, UK and Australia.
Which laws regulate peptides in Canada?
Three layers of federal law apply, all administered by Health Canada:
- The Food and Drugs Act and Food and Drug Regulations. These set the rules for selling, advertising, importing and manufacturing drugs. A drug needs market authorization, shown by a DIN, before it can be sold.[1]
- The Prescription Drug List (PDL). Health Canada keeps this list of medicinal ingredients that need a prescription. Ingredients on it can only be sold with a prescription from a licensed practitioner.[2]
- The Natural Health Products Regulations. These cover vitamins, amino acids and herbal products. Single amino acids can qualify, but Schedule 2 excludes any “substance that is administered by puncturing the dermis.” That means an injectable peptide cannot be sold as a natural health product.[5]
Provinces and territories add a fourth layer: they license pharmacists and doctors, and they regulate compounding as part of professional practice.
Are injectable peptides prescription drugs in Canada?
Yes, according to Health Canada. Its August 1, 2025 advisory states that injectable peptides are regulated as prescription drugs in Canada, and that selling unauthorized drugs is illegal.[4] Its April 9, 2026 advisory repeats that peptides are “generally regulated as prescription drugs.”[3]
The table below summarizes where common compounds stand.
| Compound | Authorized product in Canada? | How it can be obtained |
|---|---|---|
| Semaglutide | Yes (brand and, since April 2026, generic) | Prescription, licensed pharmacy |
| Tirzepatide | Yes | Prescription, licensed pharmacy |
| BPC-157 | No | No legal sale; seized by Health Canada |
| TB-500 | No | No legal sale; seized by Health Canada |
| Retatrutide | No (investigational) | Clinical trials only |
| Epitalon, Semax, Ipamorelin | No | No legal sale; seized by Health Canada |
The “no” entries reflect products listed by name in Health Canada’s 2025 seizure advisory, which covered more than 40 unauthorized injectable peptides.[4]
What does “research use only” mean under Canadian law?
Nothing protective. Health Canada’s April 9, 2026 advisory says it keeps finding products labelled “For Research Use Only – Not for Human Consumption,” and that this labelling “does not make these products legal or exempt from regulatory requirements.”[3]
The same advisory lists the risks Health Canada links to unauthorized peptides, including hormonal and blood sugar imbalance, liver or kidney damage, blood clots and tumour growth, as well as infection, allergic reactions, wrong doses and contamination.[3] Health Canada advises people to check for a DIN and to buy prescription drugs only from licensed pharmacies.[3]
For more on this labelling tactic, see our guide to online peptide sales and legal risks.
Can you import peptides into Canada for personal use?
Mostly no. Health Canada’s personal-use guidance (GUI-0116) says that, generally, residents of Canada are not allowed to bring prescription drugs into the country, whether they carry them across the border or receive them by mail or courier.[6]
There are four narrow exceptions for residents, each limited to a personal quantity:[6]
- Drugs prescribed and filled in Canada that you take abroad and bring back.
- Continuing a treatment that was started abroad.
- Taking part in a foreign-sponsored clinical trial.
- Recently landed immigrants or refugees continuing their treatment.
Visitors may bring a personal quantity for their own use. In all cases the limit is “no more than a 90-day supply or a single course of treatment, whichever is less,” and repeated shipments that exceed 90 days of supply in 90 days can be treated as commercial importing.[6] Products must also be in pharmacy, hospital or original retail packaging that clearly identifies the contents.[6]
An unauthorized research peptide does not fit any of these exceptions. Our peptide import laws guide compares customs rules in other countries.
How does the Special Access Program work?
The Special Access Program (SAP) is the legal route for a drug that is not sold in Canada. A practitioner, not a patient, applies. Requests must involve a serious or life-threatening condition where conventional treatments have failed, are unsuitable or are unavailable in Canada.[7]
SAP is not a workaround for wellness or performance use. It is a case-by-case medical emergency pathway, and Health Canada decides each request. Clinical trials, which Health Canada also authorizes, are the other route to an investigational peptide such as retatrutide.
What has Health Canada said about compounded and fake GLP-1s?
Health Canada took three notable actions on GLP-1 peptides in 2025 and 2026:
- June 2, 2025: In a letter to provincial and territorial partners, Health Canada said some pharmacies were still compounding injectable GLP-1s without a shortage, “which is not permitted.” It said no chemically synthesized semaglutide is authorized in Canada, that using it outside unique patient-specific cases counts as manufacturing under its compounding policy (POL-0051), and that it is taking compliance and enforcement action.[8] The letter also noted that Health Canada requested the recall of two compounded semaglutide-with-pyridoxine (vitamin B6) products on January 21, 2025.[8]
- January 21, 2026: A public advisory warned about fake and unauthorized GLP-1 products sold in stores and online, including websites misusing Health Canada’s logo. It named the authorized products: semaglutide (Ozempic, Rybelsus, Wegovy) and tirzepatide (Mounjaro, Zepbound).[9]
- April 28, 2026: Health Canada authorized the first generic semaglutide injection, for adults with type 2 diabetes, making Canada the first G7 country to do so.[10]
Generic approval changes the price picture, but not the legal one: generic semaglutide still needs a prescription and a licensed pharmacy. Our generic semaglutide and compounded semaglutide vs Ozempic guides cover the U.S. side.
How does Canada compare with the United States?
The main difference is compounding. In the U.S., the FD&C Act sets out section 503A and 503B compounding with lists of allowed bulk substances, which is why FDA’s peptide category decisions matter so much there (see 503A vs 503B compounding). Canada has no equivalent bulk list. Instead, Health Canada judges whether an activity is compounding or manufacturing using POL-0051, and it has said that compounding “must not be used to bypass the federal drug review and approval system.”[8]
Both countries treat unauthorized injectable peptides sold to the public as illegal drugs, and both reject the “research use only” label as a defence.
The bottom line
Canada’s rules are simple on paper. If a peptide is meant to be injected into a person, it is a drug. If it has no DIN, it is unauthorized, and selling it is illegal. Personal importing of prescription drugs is mostly off-limits for residents, and SAP is reserved for serious illness under a practitioner’s care.
This is general information, not legal advice. Rules and advisories change, so check Health Canada’s website, and talk to a licensed pharmacist or doctor about your own situation.
